Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Chromadex Corp CS (CDXC)

Chromadex Corp CS (CDXC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 572,873
  • Shares Outstanding, K 76,383
  • Annual Sales, $ 83,570 K
  • Annual Income, $ -4,940 K
  • EBIT $ 0 M
  • EBITDA $ 1 M
  • 60-Month Beta 1.88
  • Price/Sales 6.87
  • Price/Cash Flow N/A
  • Price/Book 16.71

Options Overview Details

View History
  • Implied Volatility 102.13% ( +11.48%)
  • Historical Volatility 158.95%
  • IV Percentile 46%
  • IV Rank 13.67%
  • IV High 648.82% on 08/08/24
  • IV Low 15.54% on 08/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 967
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 6,526
  • Open Int (30-Day) 6,566

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.02
  • Number of Estimates 2
  • High Estimate 0.04
  • Low Estimate 0.00
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.39 +128.61%
on 10/23/24
7.79 -0.51%
on 11/21/24
+4.29 (+123.99%)
since 10/21/24
3-Month
3.10 +150.00%
on 09/04/24
7.79 -0.51%
on 11/21/24
+4.31 (+124.96%)
since 08/21/24
52-Week
1.32 +487.12%
on 12/13/23
7.79 -0.51%
on 11/21/24
+6.31 (+438.19%)
since 11/21/23

Most Recent Stories

More News
5 Stocks With Recent Price Strength to Tap Wall Street Rally

U.S. stock markets started November, adding more steam to the ongoing rally. The primary reason was the anticipation of Donald Trump becoming the 47th president of the country. On Nov 5, Trump clinched...

CORT : 56.45 (+0.64%)
SEZL : 416.13 (+6.67%)
CDXC : 7.56 (+0.80%)
TILE : 25.71 (+0.94%)
BGC : 10.10 (-0.10%)
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss...

CDXC : 7.56 (+0.80%)
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.

CDXC : 7.56 (+0.80%)
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced that senior management will participate at the 35 th annual ROTH Capital Partners...

CDXC : 7.56 (+0.80%)
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to...

CDXC : 7.56 (+0.80%)
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside (NR) and...

CDXC : 7.56 (+0.80%)
A Letter from the ChromaDex Chief Executive Officer

The following is issued on behalf of ChromaDex (NASDAQ: CDXC).

CDXC : 7.56 (+0.80%)
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational...

CDXC : 7.56 (+0.80%)
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed...

CDXC : 7.56 (+0.80%)
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB). Dr....

CDXC : 7.56 (+0.80%)

Business Summary

ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is...

See More

Key Turning Points

3rd Resistance Point 8.00
2nd Resistance Point 7.81
1st Resistance Point 7.65
Last Price 7.56
1st Support Level 7.30
2nd Support Level 7.11
3rd Support Level 6.95

See More

52-Week High 7.79
Last Price 7.56
Fibonacci 61.8% 5.32
Fibonacci 50% 4.55
Fibonacci 38.2% 3.79
52-Week Low 1.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar